Financial News Discussion of SVNT - Savient Pharmaceuticals, Incorporated on The Opening Bell on Fox Business

Financial News for Savient Pharmaceuticals, Incorporated (SVNT)

SVNT 3/18/2010 1:15PM 52 Week Price Range Market Capitalization Dividend Yield Recent Dividend
$14.80 $4.38 — $16.62 $1.0 Billion n/a n/a

Want to Sharpen Your Investing?

Learn how Ockham can help investors make informed decisions and slice through the noise. Learn more about Ockham's services.

Sign Up Now for Ockham's Stock Analysis and News Services

Explore Why Ockham?

Quality Analysis
Ockham has fundamental valuations on over 5000 companies which we distribute, to our clients via highly-focused equity reports, weekly newsletters, and analysts' daily market commentary blogs. (Learn More)
Crowd Sentiment
Through our partnership with The Motley Fool, Ockham provides the most robust data on investors' sentiment of individual stocks. This indicator, along with our valuations and our news tracking, helps our clients make informed investment decisions. (Learn More)
Financial News Slicing
With the influx of noise in our lives, it can be exceedingly difficult to separate the essential news from everything else. Ockham's RazorWire tool "slices" through business television and impactful blogs to provide you with the clearest information possible. (Learn More)
Savient Pharmaceuticals, Inc. was discussed on The Opening Bell on Fox Business which was originally produced by Fox Business on 2/13/2009
If you are an investor, then The Opening Bell on Fox Business hosted by Alexis Glick on Fox Business is a must watch. Savient Pharmaceuticals, Incorporated was discussed on 2/13/09 show.

Savient Pharmaceuticals, Incorporated is in the news. Find out how this impacts SVNT trading on Ockham Research.

Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching,

“Pricing a secondary common stock offering and investors not necessary lie liking the dilutive effect of the move and SAVIENT PHARMACEUTICALS hit hard and the company announcing fda is reviewing one of its gout drugs and others i'm watching, ” The Opening Bell on Fox Business Feb 13, 2009 9:33 AM
Some important items we've observed: